RU2008143547A - Тиазолилдигидроциклопентапиразолы для применения в качестве ингибиторов pi3-киназы - Google Patents

Тиазолилдигидроциклопентапиразолы для применения в качестве ингибиторов pi3-киназы Download PDF

Info

Publication number
RU2008143547A
RU2008143547A RU2008143547/04A RU2008143547A RU2008143547A RU 2008143547 A RU2008143547 A RU 2008143547A RU 2008143547/04 A RU2008143547/04 A RU 2008143547/04A RU 2008143547 A RU2008143547 A RU 2008143547A RU 2008143547 A RU2008143547 A RU 2008143547A
Authority
RU
Russia
Prior art keywords
alkyl
group
aryl
cycloalkyl
optionally
Prior art date
Application number
RU2008143547/04A
Other languages
English (en)
Russian (ru)
Inventor
Штефен БРАЙТФЕЛЬДЕР (DE)
Штефен БРАЙТФЕЛЬДЕР
Удо МАЙЕР (DE)
Удо МАЙЕР
Кристоф ХЁНКЕ (DE)
Кристоф Хёнке
Анне Т. ЙЁРГЕНСЕН (DK)
Анне Т. ЙЁРГЕНСЕН
Александер ПАУЧ (DE)
Александер Пауч
Трикси БРАНДЛЬ (CH)
Трикси Брандль
Маттиас ГРАУЕРТ (DE)
Маттиас Грауерт
Маттиас ХОФФМАНН (DE)
Маттиас Хоффманн
Штефан ШОЙЕРЕР (DE)
Штефан Шойерер
Клаус ЭРБ (DE)
Клаус ЭРБ
Михаэль ПИПЕР (DE)
Михаэль ПИПЕР
Инго ПРАГСТ (DE)
Инго ПРАГСТ
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх (De)
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх (De), Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх (De)
Publication of RU2008143547A publication Critical patent/RU2008143547A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2008143547/04A 2006-04-06 2007-03-27 Тиазолилдигидроциклопентапиразолы для применения в качестве ингибиторов pi3-киназы RU2008143547A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06112298.2 2006-04-06
EP06112298 2006-04-06

Publications (1)

Publication Number Publication Date
RU2008143547A true RU2008143547A (ru) 2010-05-20

Family

ID=36764026

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008143547/04A RU2008143547A (ru) 2006-04-06 2007-03-27 Тиазолилдигидроциклопентапиразолы для применения в качестве ингибиторов pi3-киназы

Country Status (15)

Country Link
US (1) US7517995B2 (cg-RX-API-DMAC7.html)
EP (1) EP2007382A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009532415A (cg-RX-API-DMAC7.html)
KR (1) KR20080111118A (cg-RX-API-DMAC7.html)
CN (1) CN101460167A (cg-RX-API-DMAC7.html)
AR (1) AR060267A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007236045A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0710306A2 (cg-RX-API-DMAC7.html)
CA (1) CA2647292A1 (cg-RX-API-DMAC7.html)
IL (1) IL194494A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008012534A (cg-RX-API-DMAC7.html)
RU (1) RU2008143547A (cg-RX-API-DMAC7.html)
TW (1) TW200806679A (cg-RX-API-DMAC7.html)
WO (1) WO2007115931A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200807713B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004016179A1 (de) * 2004-03-30 2005-10-20 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von proliferativen Prozessen
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US20070259855A1 (en) * 2006-04-06 2007-11-08 Udo Maier Thiazolyl-dihydro-indazole
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US20110230472A1 (en) * 2008-08-29 2011-09-22 Shionogi & Co., Ltd. Ring-fused azole derivative having pi3k-inhibiting activity
CA2738868C (en) 2008-10-01 2017-01-17 Novartis Ag Smoothened antagonism for the treatment of hedgehog pathway-related disorders
JP5579724B2 (ja) * 2008-10-17 2014-08-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ホスファチジルイノシトール−3−キナーゼ(pi−3キナーゼ)阻害剤としてのテトラ−アザ−複素環
WO2010125799A1 (ja) 2009-04-27 2010-11-04 塩野義製薬株式会社 Pi3k阻害活性を有するウレア誘導体
EA201200087A1 (ru) 2009-07-02 2012-07-30 Новартис Аг 2-карбоксамиды циклоаминомочевин, которые являются ингибиторами pi3k
US20140213630A1 (en) * 2011-03-08 2014-07-31 Thomas Diacovo Methods and pharmaceutical compositions for treating lymphoid malignancy
JP2014114212A (ja) * 2011-03-29 2014-06-26 Dainippon Sumitomo Pharma Co Ltd 新規ベンズイミダゾール誘導体
EA027855B1 (ru) * 2012-04-17 2017-09-29 Гайлид Сайэнсиз, Инк. Соединения и способы для противовирусной терапии
JP2022515256A (ja) 2018-12-25 2022-02-17 ソル - ゲル テクノロジーズ リミテッド Egfr阻害剤を含む組成物による皮膚障害の治療

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL357099A1 (en) 2000-02-07 2004-07-12 Abbott Gmbh & Co.Kg 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
AR038703A1 (es) 2002-02-28 2005-01-26 Novartis Ag Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
MXPA05000453A (es) 2002-07-10 2005-03-23 Applied Research Systems Derivados de benceno fusionados a azolidinona-vinilo.
WO2004029055A1 (en) 2002-09-30 2004-04-08 Bayer Pharmaceuticals Corporation Fused azole-pyrimidine derivatives
CA2504335A1 (en) 2002-10-30 2004-05-13 Toppan Printing Co., Ltd. Apparatus of wiring pattern, inspection method, detection apparatus, detection method
BR0316386A (pt) 2002-12-06 2005-09-27 Warner Lambert Co Benzoxazin-3-onas e seus derivados como inibidores de p13k
WO2004056820A1 (en) 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
CA2528938A1 (en) 2003-06-13 2005-02-24 Zentaris Gmbh Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof
GB0315966D0 (en) 2003-07-08 2003-08-13 Cyclacel Ltd Compounds
DE10344223A1 (de) 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
US7691888B2 (en) 2004-10-07 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-indazole
UY29149A1 (es) 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles

Also Published As

Publication number Publication date
US7517995B2 (en) 2009-04-14
AU2007236045A1 (en) 2007-10-18
EP2007382A1 (de) 2008-12-31
AR060267A1 (es) 2008-06-04
MX2008012534A (es) 2008-10-10
TW200806679A (en) 2008-02-01
BRPI0710306A2 (pt) 2011-08-09
KR20080111118A (ko) 2008-12-22
US20070238730A1 (en) 2007-10-11
IL194494A0 (en) 2009-08-03
WO2007115931A8 (de) 2008-06-12
JP2009532415A (ja) 2009-09-10
CN101460167A (zh) 2009-06-17
ZA200807713B (en) 2009-08-26
CA2647292A1 (en) 2007-10-18
WO2007115931A1 (de) 2007-10-18

Similar Documents

Publication Publication Date Title
RU2008143548A (ru) Тиазолилдигидрохиназолины
RU2008143552A (ru) Тиазолилдигидроиндазолы
RU2008143557A (ru) Тиазолилдигидроиндазолы
RU2007116861A (ru) P13-киназы
KR101088848B1 (ko) 피라졸로〔3,4―b〕피리딘 화합물, 및 이의포스포디에스테라제 억제제로서의 용도
EP2380891B1 (de) Substituierte Piperidino-Dihydrothienopyrimidine
ES2331119T3 (es) Compuestos de pirazolo(3,4-b)piridina, y su uso como inhibidores de fosfodiesterasa.
ES2715682T3 (es) Inhibidores de la autotaxina
EP2560966B1 (en) Multisubstituted aromatic compounds as inhibitors of thrombin
CN1129581C (zh) 氰基苯基衍生物
KR102616949B1 (ko) 고리형 구조를 갖는 화합물
JP5791708B2 (ja) 尿素誘導体、および特に呼吸器の疾患の治療におけるその治療的使用
JP2006503048A5 (cg-RX-API-DMAC7.html)
JP2019516731A (ja) 第三級アミド基を有するベンズアゼピンジカルボキサミド化合物
JP6120951B2 (ja) 新規ep2受容体作動薬
JP2019520330A (ja) 第二級アミド基を有するベンズアゼピンジカルボキサミド化合物
AU2016284638B2 (en) Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
JPH09505055A (ja) サイトカイン媒介疾患治療用オキサゾール
CA2314008A1 (en) 2-benzimidazolylamine compounds as orl1-receptor agonists
JP2009532415A5 (cg-RX-API-DMAC7.html)
JP2007514704A (ja) ピラゾロ[3,4−b]ピリジン化合物およびホスホジエステラーゼ阻害剤としてのその使用
SK1852004A3 (sk) Deriváty piperazínu s účinkami antagonistu receptora CCR1
JP2008515852A5 (cg-RX-API-DMAC7.html)
US20200165257A1 (en) Inhibitors of phosphoinositide 3-kinase and histone deacetylase for treatment of cancer
JP2009532413A5 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20110602